All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Liraglutide 3.0mg: Results Timeline

Liraglutide 3.0mg results timeline from the SCALE trials. Month-by-month weight loss, metabolic improvements, and what to expect at each phase.

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

Liraglutide 3.0mg: Results Timeline custom 2026 header image for GLP-1 Weight Loss
Custom header image for Liraglutide 3.0mg: Results Timeline, GLP-1 Weight Loss, and better treatment decision-making.
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Search and AI answer brief

Practical answer: Liraglutide 3.0mg: Results Timeline

Liraglutide 3.0mg results timeline from the SCALE trials. Month-by-month weight loss, metabolic improvements, and what to expect at each phase.

Short answer

Liraglutide 3.0mg results timeline from the SCALE trials. Month-by-month weight loss, metabolic improvements, and what to expect at each phase.

Search intent

This page answers a specific GLP-1 Weight Loss question rather than a generic overview.

What to verify

semaglutide, tirzepatide, retatrutide, safety and contraindications

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

See your GLP-1 options in about 2 minutes. Free and private. See my options →

Liraglutide 3.0mg results timeline from the SCALE trials. Month-by-month weight loss, metabolic improvements, and what to expect at each phase.

Liraglutide 3.0mg results follow a predictable pattern, with the fastest weight loss in months 2 through 5, a gradual slowing through months 6 to 9, and a plateau phase from month 10 onward. The SCALE clinical trials provide detailed data at multiple timepoints, giving us a clear picture of what to expect. Here is a thorough month-by-month breakdown.

The Big Picture: SCALE Trial[1] Weight Loss Curve

In the SCALE Obesity and Prediabetes trial, patients on liraglutide 3.0mg lost an average of 8.0% of body weight over 56 weeks. But that average masks a clear curve with distinct phases.

SCALE Trial Weight Loss by Timepoint (Liraglutide 3.0mg)
Timepoint Mean Weight Loss (%) Approximate lbs Lost (220 lb baseline) Phase
Week 4 (end of titration) 1.5 to 2.0% 3 to 4 lbs Titration / adaptation
Week 8 3.0 to 3.5% 7 to 8 lbs Early response
Week 16 5.5 to 6.0% 12 to 13 lbs Peak loss rate
Week 28 7.0 to 7.5% 15 to 17 lbs Continued loss, slowing pace
Week 40 7.5 to 8.0% 17 to 18 lbs Approaching plateau
Week 56 8.0% 17 to 18 lbs Plateau / maintenance

Month 1: Titration and First Signals

During the first month, you're titrating from 0.6mg through 2.4mg and reaching 3.0mg around week 5. Weight loss during this phase is modest (2 to 4 lbs) because you aren't yet at the therapeutic dose for most of the month.

GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Illustration for Liraglutide 3.0mg: Results Timeline

What you'll notice:

  • Gradual appetite reduction that becomes more pronounced each week
  • GI side effects that peak at each new dose level and then settle
  • Possibly some water weight loss from eating less overall
  • Increased awareness of portion sizes and fullness cues

Think of month 1 as the foundation. The scale may not move dramatically, but the biological groundwork for months 2 through 5 is being laid.

Months 2 to 3: The Acceleration Phase

This is when most patients see their fastest rate of loss. You're fully on the 3.0mg maintenance dose, and the appetite-suppressing effects are at their strongest. Caloric intake is naturally lower because you genuinely want to eat less.

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →

Expected results:

  • 4 to 8 lbs lost per month (1 to 2 lbs per week)
  • Noticeable clothing fit changes, especially around the waist
  • Improved energy and mood as weight decreases
  • Lab markers beginning to shift: fasting glucose dropping, triglycerides improving

This is also when your physician will evaluate your response. If you have lost 4% or more of your starting body weight by week 12, you're considered an adequate responder and should continue.

Months 4 to 6: Steady Progress, Slowing Pace

Weight loss continues but the rate naturally decelerates. This isn't a sign of failure. As you lose weight, your body requires fewer calories to maintain its new mass, so the caloric deficit narrows even if your eating habits remain consistent.

  • 2 to 4 lbs lost per month
  • Cumulative loss typically 12 to 16 lbs by month 6
  • Blood pressure improvements often measurable at this stage
  • Patients with prediabetes may see HbA1c normalize
  • Physical endurance and exercise capacity improving

Months 7 to 9: Approaching the Plateau

Most patients approach or reach their weight loss nadir during this window. The scale may move very slowly or appear to stall for 2 to 3 weeks at a time.

  • 0 to 2 lbs lost per month
  • Body composition may still be shifting even without scale changes (losing fat, maintaining or building muscle if exercising)
  • Metabolic benefits continue to accrue
  • Some patients experience a "set point" sensation where their body resists further loss

If you aren't satisfied with results at this stage, your physician may discuss adding structured exercise programming, working with a dietitian, or considering combination approaches. breaking through a weight loss plateau on GLP-1

Months 10 to 12 and Beyond: Maintenance

The SCALE trial showed that weight loss was maintained through week 56 with continued liraglutide use. The goal shifts from active weight loss to weight maintenance, which is itself a significant achievement. Studies show that maintaining a 5 to 10% weight loss for one year or longer dramatically reduces long-term cardiovascular and metabolic risk.

During the maintenance phase:

  • Continue 3.0mg daily unless your physician recommends a change
  • Maintain consistent eating and exercise habits
  • Watch for gradual weight creep, which can indicate dietary drift or metabolic adaptation
  • Regular lab monitoring every 3 to 6 months

What Happens After You Stop

The SCALE Maintenance extension data showed that patients who discontinued liraglutide regained approximately half of their lost weight within 12 months. This underscores why liraglutide is generally considered long-term therapy rather than a short course.

Frequently Asked Questions

What if I am losing weight faster or slower than this timeline?

Individual variation is significant. Some patients lose 12% or more, while others lose closer to 5%. Both can be clinically beneficial. The averages from SCALE represent the middle of a wide distribution.

Will the medication stop working after a year?

Liraglutide doesn't "stop working." The plateau reflects a new metabolic equilibrium. The drug continues suppressing appetite and maintaining your lower weight. Without it, most patients would regain.

Can I restart liraglutide later if I stop and regain?

Yes. Patients who restart liraglutide after a break typically respond again, though they need to re-titrate from 0.6mg. The magnitude of weight loss on a second course may vary. restarting liraglutide after a break

Are men and women results different?

SCALE trial data showed similar percentage weight loss between men and women, though men tended to lose slightly more absolute weight due to higher baseline body weights. Hormonal factors can influence the pace but generally not the overall efficacy.

Does age affect the timeline?

Older adults (60+) may lose weight slightly more slowly due to lower metabolic rates, but the medication remains effective across age groups studied in the SCALE program (18 to 65 years in most cohorts).

Medical References

  1. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]

Monitor Your Timeline With FormBlends

At FormBlends, we track your results against clinical benchmarks and adjust your plan accordingly. If you're ahead of schedule, on pace, or need additional support, our physicians provide the guidance you need at every stage.

Want to see where you stand on the timeline? Schedule a consultation with a FormBlends physician today.

Disclaimer: This content is for educational purposes only and doesn't constitute medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider before starting, stopping, or changing any medication. Individual results vary. Liraglutide is a prescription medication and should only be used under the supervision of a licensed healthcare provider.

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →

Research Snapshot

Provider comparison
Page type
Provider comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
Retatrutide evidence source
Official source
Semaglutide evidence source
Official source
Tirzepatide evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For Liraglutide 3.0mg: Results Timeline, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Direct answer

Liraglutide 3.0mg: Results Timeline research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

FormBlends Editorial Context

Reviewed May 14, 2026

Liraglutide 3.0mg results timeline from the SCALE trials. Month-by-month weight loss, metabolic improvements, and what to expect at each phase. "Liraglutide 3.0mg: Results Timeline" is most useful when you treat it as decision prep, not a shortcut. The page is built around patient education and clinical context, with the highest-value checks sitting around the main claim, safety boundary, and next practical step. Because this article has 9 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. If the answer affects treatment, cost, pharmacy choice, or dosing, bring the specifics to a licensed clinician before acting.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for Liraglutide 3.0mg

For this glp-1 weight loss page, the 2026 refresh focuses on semaglutide, tirzepatide, retatrutide, safety signals, liraglutide, 0mg so the article stays close to the question behind "Liraglutide 3.0mg".

The useful details are the practical ones: what to verify, what changes risk or cost, and which details separate Liraglutide 3.0mg from nearby GLP-1, peptide, hormone, or provider-comparison searches.

Readers can use the added context to bring sharper questions to a licensed provider before making a treatment, cost, or care decision.

Liraglutide 3.0mg custom 2026 image for glp-1 weight loss on FormBlends

Custom 2026 image for Liraglutide 3.0mg, glp-1 weight loss, and better treatment decision-making.

Image description: Unique image for this page covering Liraglutide 3.0mg, glp-1 weight loss, safety, cost, provider selection, and patient decision-making.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.